KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Cash (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Change in Cash readings, the most recent being $185.0 million for Q1 2026.

  • On a quarterly basis, Change in Cash rose 111.54% to $185.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.0 billion, a 258.08% increase, with the full-year FY2025 number at $256.0 million, up 245.95% from a year prior.
  • Change in Cash hit $185.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $1.4 billion in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $1.4 billion in Q4 2025 to a low of -$1.6 billion in Q1 2025.
  • Median Change in Cash over the past 5 years was $52.0 million (2022), compared with a mean of $90.8 million.
  • Biggest five-year swings in Change in Cash: crashed 1365.38% in 2023 and later skyrocketed 7616.67% in 2025.
  • Teva Pharmaceutical Industries' Change in Cash stood at $576.0 million in 2022, then skyrocketed by 69.62% to $977.0 million in 2023, then tumbled by 101.84% to -$18.0 million in 2024, then skyrocketed by 7616.67% to $1.4 billion in 2025, then plummeted by 86.33% to $185.0 million in 2026.
  • The last three reported values for Change in Cash were $185.0 million (Q1 2026), $1.4 billion (Q4 2025), and $42.0 million (Q3 2025) per Business Quant data.